Clinical Trial

Trial Protocol ID USOR 23107_OP-1250-301_OPERA-01 *STAR* On hold as of 10/03/2024

Trial Description

A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 inhibitor Therapy (OPERA-01) 

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Disease Types

Sponsors

  • Olema Pharmaceuticals, Inc.
  • PPD Investigator Services, LLC

ClinicalTrials.gov NCT ID

  • NCT06016738